{"id":"W3170783707","doi":"10.1200/jco.2021.39.15_suppl.8018","title":"Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Vancouver General Hospital; CancerCare Manitoba; University of Calgary; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"Karyopharm Therapeutics","keywords":"Pomalidomide; Medicine; Lenalidomide; Refractory (planetary science); Internal medicine; Dexamethasone; Regimen; Phases of clinical research; Gastroenterology; Bortezomib; Multiple myeloma; Pharmacology; Oncology; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005222813,0.0005105124,0.0007587948,0.0003089678,0.0002237274,0.0004439227,0.0005992707,0.0005436919,0.003472107],"category_scores_gemma":[0.0003216398,0.0002368533,0.0004459001,0.0002366995,0.0003066501,0.0003781538,0.0002809249,0.0012232,0.000647347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006757446,"about_ca_system_score_gemma":0.0007083208,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005612899,"about_ca_topic_score_gemma":0.002254865,"domain_scores_codex":[0.9998202,0.00007102548,0.00001212149,0.00003407161,0.00002745436,0.00003514763],"domain_scores_gemma":[0.9998463,0.00002339398,0.00003650273,0.00000908675,0.000006802442,0.00007783974],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2742431,0.03657896,0.027463,0.001524962,0.001073069,0.001324224,0.0004810913,0.003967308,0.07228721,0.0007329732,0.008438567,0.5718856],"study_design_scores_gemma":[0.2860694,0.5481787,0.09667858,0.0003050171,0.0008962913,0.002839279,0.0002085468,0.003190123,0.0196465,0.0006018833,0.04132762,0.00005817405],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9869709,0.006956684,0.0004581905,0.0005672789,0.00008343354,0.001151932,0.000653798,0.0001313296,0.003026466],"genre_scores_gemma":[0.9913877,0.002737272,0.001227695,0.0007163311,0.00005399753,0.0006706183,0.0009957855,0.00001531594,0.002195193],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003472107,"threshold_uncertainty_score":0.0116154,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1983294157969046,"score_gpt":0.5080308278211916,"score_spread":0.309701412024287,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}